Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
Condition(s):Relapsed Refractory Multiple MyelomaLast Updated:January 16, 2024Suspended
Hide Studies Not Open or Pending
Condition(s):Relapsed Refractory Multiple MyelomaLast Updated:January 16, 2024Suspended
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:May 4, 2022Withdrawn
Condition(s):Relapsed Multiple Myeloma; Relapsed-Refractory Multiple MyelomaLast Updated:June 8, 2023Terminated
Condition(s):Multiple MyelomaLast Updated:November 18, 2019Completed
Condition(s):Relapsed and/or Relapsed-refractory Multiple MyelomaLast Updated:October 23, 2020Terminated
Condition(s):Multiple MyelomaLast Updated:March 25, 2019Withdrawn
Condition(s):Multiple MyelomaLast Updated:December 7, 2015Completed
Condition(s):Relapse Multiple Myeloma; Multiple MyelomaLast Updated:November 26, 2021Withdrawn
Condition(s):Multiple MyelomaLast Updated:March 26, 2024Recruiting
Condition(s):Myeloma, Multiple; Myeloma-MultipleLast Updated:May 12, 2021Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.